CA3081988A1 - Supplement including gamma-aminobutyric acid for restoring growth hormone levels - Google Patents
Supplement including gamma-aminobutyric acid for restoring growth hormone levels Download PDFInfo
- Publication number
- CA3081988A1 CA3081988A1 CA3081988A CA3081988A CA3081988A1 CA 3081988 A1 CA3081988 A1 CA 3081988A1 CA 3081988 A CA3081988 A CA 3081988A CA 3081988 A CA3081988 A CA 3081988A CA 3081988 A1 CA3081988 A1 CA 3081988A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acids
- growth hormone
- amino acid
- user
- mass range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 229960003692 gamma aminobutyric acid Drugs 0.000 title claims abstract description 26
- 102000018997 Growth Hormone Human genes 0.000 title claims abstract description 19
- 108010051696 Growth Hormone Proteins 0.000 title claims abstract description 19
- 239000000122 growth hormone Substances 0.000 title claims abstract description 16
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 239000013589 supplement Substances 0.000 title claims description 20
- 229940024606 amino acid Drugs 0.000 claims abstract description 60
- 150000001413 amino acids Chemical class 0.000 claims abstract description 58
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 26
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims abstract description 22
- 239000004475 Arginine Substances 0.000 claims abstract description 21
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims abstract description 21
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 21
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 21
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 19
- 239000004472 Lysine Substances 0.000 claims abstract description 19
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960003104 ornithine Drugs 0.000 claims abstract description 17
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 16
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 16
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 15
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims abstract description 14
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 13
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 11
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960000310 isoleucine Drugs 0.000 claims abstract description 11
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000004474 valine Substances 0.000 claims abstract description 10
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 8
- 230000037406 food intake Effects 0.000 claims abstract description 7
- 150000005693 branched-chain amino acids Chemical class 0.000 claims abstract description 4
- 235000001014 amino acid Nutrition 0.000 claims description 58
- 235000009697 arginine Nutrition 0.000 claims description 20
- 229960003121 arginine Drugs 0.000 claims description 20
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 19
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 19
- 239000000854 Human Growth Hormone Substances 0.000 claims description 19
- 229960002743 glutamine Drugs 0.000 claims description 18
- 229960003646 lysine Drugs 0.000 claims description 18
- 235000018977 lysine Nutrition 0.000 claims description 15
- 229960003136 leucine Drugs 0.000 claims description 12
- 235000005772 leucine Nutrition 0.000 claims description 10
- 239000004471 Glycine Substances 0.000 claims description 9
- 229960002449 glycine Drugs 0.000 claims description 9
- 229960004295 valine Drugs 0.000 claims description 9
- 235000014393 valine Nutrition 0.000 claims description 9
- 241000282412 Homo Species 0.000 claims description 8
- 235000014705 isoleucine Nutrition 0.000 claims description 7
- 229930182816 L-glutamine Natural products 0.000 claims description 4
- 235000019766 L-Lysine Nutrition 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 3
- 229930064664 L-arginine Natural products 0.000 claims description 3
- 235000014852 L-arginine Nutrition 0.000 claims description 3
- 229930182844 L-isoleucine Natural products 0.000 claims description 3
- 235000016709 nutrition Nutrition 0.000 claims 5
- 230000009469 supplementation Effects 0.000 claims 5
- 230000001965 increasing effect Effects 0.000 description 17
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 11
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 11
- 235000004554 glutamine Nutrition 0.000 description 10
- 210000003205 muscle Anatomy 0.000 description 10
- 230000000580 secretagogue effect Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 230000003028 elevating effect Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 102000005157 Somatostatin Human genes 0.000 description 6
- 108010056088 Somatostatin Proteins 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 6
- 229960000553 somatostatin Drugs 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 5
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 5
- 206010062767 Hypophysitis Diseases 0.000 description 5
- 101710142969 Somatoliberin Proteins 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 210000004198 anterior pituitary gland Anatomy 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000003635 pituitary gland Anatomy 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000003292 diminished effect Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010056438 Growth hormone deficiency Diseases 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- -1 amino acid salts Chemical class 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960004532 somatropin Drugs 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010000599 Acromegaly Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010018265 Gigantism Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical class OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Chemical class 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940106307 glutamine 200 mg Drugs 0.000 description 1
- 238000009578 growth hormone therapy Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940080800 lysine 500 mg Drugs 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000036562 nail growth Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000018052 penile erection Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 208000003068 pituitary dwarfism Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 201000010041 presbyopia Diseases 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
A nutritional supplement for ingestion by humans for restoring growth hormone levels consisting of branched chain amino acids chosen from the group leucine, isoleucine, and valine;
free form amino acids chosen from the group lysine, glutamine, ornithine, arginine, and glycine;
and the free form amino acid gamma-aminobutyric acid.
free form amino acids chosen from the group lysine, glutamine, ornithine, arginine, and glycine;
and the free form amino acid gamma-aminobutyric acid.
Description
SUPPLEMENT INCLUDING GAMMA-AMINOBUTYRIC ACID
FOR RESTORING GROWTH HORMONE LEVELS
Field This disclosure relates to the field of nutritional supplements, including supplements which elevate release of human growth hormone.
Background Until recently human growth hormone (hereinafter alternatively referred to as hGH) was available only in expensive injectable forms and benefits from the restoration of hGH levels available only to those with the ability to pay. Most recently natural substances which can trigger the release of human growth hormone from an individual's own anterior pituitary gland have become available. These are generically referred to as secretagogues.
Secretagogues have the ability to restore hGH levels, potentially to the levels found in youth.
See for reference the book entitled "Grow Young With hGH" by Dr. Ronald Klatz, President of the American Academy of Anti-Aging, published in 1997 by Harper Collins.
In 1981 a study was published by Drs. lsidori, A., Lo Monico and Cappa (Isidori, A., et al. Current Medical Research and Opinion 7 # 7 (1981):475-481) which demonstrated that a specific combination of amino acids, when ingested orally, would cause an increase in growth hormone levels in humans. It offered a more practical and physiological approach to the previously known fact that intravenous administration of amino acids strongly stimulates the secretion of human growth hormone by the anterior pituitary gland.
Franco Salomon et al [The New England Journal of Medicine Vol. 321 (26) p.1797-1803) 1989]
carried out a six month randomized, double blind, placebo controlled trial of recombinant human growth hormone on 24 patients suffering from growth hormone deficiency.
They noticed an increase in Insulin-like Growth Factor 1 ("IGF-1"), lean body mass and reduction in fat. Metabolic rate was increased and plasma cholesterol lowered.
Date Recue/Date Received 2020-06-05 JO. L. Jorgensen et al (Lancet-Jun. 3rd, 1989 p. 1221-1225) carried out a 4 month double blind, placebo controlled, crossover study of growth hormone in 22 deficient adults.
Muscle thickness increased, fat was reduced. Renal plasma flow and glomerular filtration rates were raised from subnormal levels to levels comparable for their age. IGF-1 levels were also normalized.
In 1990 Dr. Daniel Rudman published a research paper (Rudman, D., et al.
"Effects of Human growth Hormone in men over 60 years Old", New England Journal of Medicine, 323 (1990): 1-6) which showed that twelve healthy men aged between 61 and 81, following six months of human growth hormone therapy, had age reversal effects on lean body mass and adipose tissue mass equivalent in magnitude to changes attributable to ten to twenty years of aging. In addition, Dr. Rudman et al noted that alterations in body composition, caused by growth hormone deficiency as we age, can be reversed by replacement doses of hormone in other experiments in rodents, children and adults 20 to 50 years old. Dr. Rudman also noted that "these findings suggest that the atrophy of the lean body mass and its (the body's) component organs and the enlargement of the mass of adipose tissue that are characteristic of the elderly results at least in part from diminished secretion of growth hormone. If so, the age-related changes in body composition should be correctable in part by the administration of human growth hormone, now readily available as a bio-synthetic product".
The primary purpose of hGH is that of stimulating growth, cell repair and regeneration. Once the growth period is over, its primary function becomes that of cell regeneration and repair, helping to regenerate skin, bones, heart, lungs, liver and kidneys to their former youthful cell levels. Elevating hGH levels appears to benefit the immune system. It has also been reported the risk factors for heart attack and stroke may be potentially diminished.
Some patients with emphysema have reported that they are less short of breath. Dr. Rudman's study also demonstrated that bone density in the lumbar spine can improve. It has also been shown that wrinkled skin diminishes. Others have reported improvement in presbyopia (the difficulty in focusing due to hardening of the lenses as we age) with some reporting restoration of hair colour and growth. hGH appears to selectively reduce the fat around the abdomen, hips, waist and thighs while at the same time increasing muscle mass. In Dr. Rudman's study, after six
FOR RESTORING GROWTH HORMONE LEVELS
Field This disclosure relates to the field of nutritional supplements, including supplements which elevate release of human growth hormone.
Background Until recently human growth hormone (hereinafter alternatively referred to as hGH) was available only in expensive injectable forms and benefits from the restoration of hGH levels available only to those with the ability to pay. Most recently natural substances which can trigger the release of human growth hormone from an individual's own anterior pituitary gland have become available. These are generically referred to as secretagogues.
Secretagogues have the ability to restore hGH levels, potentially to the levels found in youth.
See for reference the book entitled "Grow Young With hGH" by Dr. Ronald Klatz, President of the American Academy of Anti-Aging, published in 1997 by Harper Collins.
In 1981 a study was published by Drs. lsidori, A., Lo Monico and Cappa (Isidori, A., et al. Current Medical Research and Opinion 7 # 7 (1981):475-481) which demonstrated that a specific combination of amino acids, when ingested orally, would cause an increase in growth hormone levels in humans. It offered a more practical and physiological approach to the previously known fact that intravenous administration of amino acids strongly stimulates the secretion of human growth hormone by the anterior pituitary gland.
Franco Salomon et al [The New England Journal of Medicine Vol. 321 (26) p.1797-1803) 1989]
carried out a six month randomized, double blind, placebo controlled trial of recombinant human growth hormone on 24 patients suffering from growth hormone deficiency.
They noticed an increase in Insulin-like Growth Factor 1 ("IGF-1"), lean body mass and reduction in fat. Metabolic rate was increased and plasma cholesterol lowered.
Date Recue/Date Received 2020-06-05 JO. L. Jorgensen et al (Lancet-Jun. 3rd, 1989 p. 1221-1225) carried out a 4 month double blind, placebo controlled, crossover study of growth hormone in 22 deficient adults.
Muscle thickness increased, fat was reduced. Renal plasma flow and glomerular filtration rates were raised from subnormal levels to levels comparable for their age. IGF-1 levels were also normalized.
In 1990 Dr. Daniel Rudman published a research paper (Rudman, D., et al.
"Effects of Human growth Hormone in men over 60 years Old", New England Journal of Medicine, 323 (1990): 1-6) which showed that twelve healthy men aged between 61 and 81, following six months of human growth hormone therapy, had age reversal effects on lean body mass and adipose tissue mass equivalent in magnitude to changes attributable to ten to twenty years of aging. In addition, Dr. Rudman et al noted that alterations in body composition, caused by growth hormone deficiency as we age, can be reversed by replacement doses of hormone in other experiments in rodents, children and adults 20 to 50 years old. Dr. Rudman also noted that "these findings suggest that the atrophy of the lean body mass and its (the body's) component organs and the enlargement of the mass of adipose tissue that are characteristic of the elderly results at least in part from diminished secretion of growth hormone. If so, the age-related changes in body composition should be correctable in part by the administration of human growth hormone, now readily available as a bio-synthetic product".
The primary purpose of hGH is that of stimulating growth, cell repair and regeneration. Once the growth period is over, its primary function becomes that of cell regeneration and repair, helping to regenerate skin, bones, heart, lungs, liver and kidneys to their former youthful cell levels. Elevating hGH levels appears to benefit the immune system. It has also been reported the risk factors for heart attack and stroke may be potentially diminished.
Some patients with emphysema have reported that they are less short of breath. Dr. Rudman's study also demonstrated that bone density in the lumbar spine can improve. It has also been shown that wrinkled skin diminishes. Others have reported improvement in presbyopia (the difficulty in focusing due to hardening of the lenses as we age) with some reporting restoration of hair colour and growth. hGH appears to selectively reduce the fat around the abdomen, hips, waist and thighs while at the same time increasing muscle mass. In Dr. Rudman's study, after six
2 Date Recue/Date Received 2020-06-05 months of usage, without exercise, the subjects had an average 8% increase in lean muscle mass and a 14.4% loss of fat.
Dr. Cass Terry and Dr. E. Chein reported on the effects of elevating hGH
levels by injection. They showed high frequency-low dose injections of hGH elevated IGF-1 levels.
Analyzing the clinical effects of elevating hGH in 202 patients (age 39-74) they showed 75% of the individuals described an increase and improvement in sexual potency as well as frequency of sexual relations, while 62% described improvement in duration of penile erection.
Energy levels were improved in 84% of individuals and muscle strength improved in 88%. A 71%
increase in healing capacity was noted.
It appears that hGH not only has the ability to restore sexual potency and sexuality in older men, but acts as a mood elevator, restoring a youthful sense of wellness as well as improving sleep. With its potential for affecting cell regeneration and repair, healing of injuries should improve.
hGH, alternatively referred to herein by its medical name Somatotropin, is produced in the anterior pituitary gland situated just below the hypothalamus which is itself situated just below the cerebral cortex of the brain. hGH is one of several hormones secreted by the anterior pituitary gland and, as noted above, influences the growth, regeneration and repair of cells, bones, muscles and organs throughout the body throughout life. Production peaks at adolescence when accelerated growth is occurring and if growing children are deficient in human growth hormone, they remain as pituitary dwarfs. If they have too much they exhibit gigantism (acromegaly).
As is the case with many of our other hormones or their pre-cursors, such as testosterone, oestrogen, progesterone, DHEA and melatonin, hGH levels decline with age.
Therapeutically, many of these hormones can be replaced to offset some of the effects of aging such as menopausal symptoms in women or erectile dysfunction in men.
Dr. Cass Terry and Dr. E. Chein reported on the effects of elevating hGH
levels by injection. They showed high frequency-low dose injections of hGH elevated IGF-1 levels.
Analyzing the clinical effects of elevating hGH in 202 patients (age 39-74) they showed 75% of the individuals described an increase and improvement in sexual potency as well as frequency of sexual relations, while 62% described improvement in duration of penile erection.
Energy levels were improved in 84% of individuals and muscle strength improved in 88%. A 71%
increase in healing capacity was noted.
It appears that hGH not only has the ability to restore sexual potency and sexuality in older men, but acts as a mood elevator, restoring a youthful sense of wellness as well as improving sleep. With its potential for affecting cell regeneration and repair, healing of injuries should improve.
hGH, alternatively referred to herein by its medical name Somatotropin, is produced in the anterior pituitary gland situated just below the hypothalamus which is itself situated just below the cerebral cortex of the brain. hGH is one of several hormones secreted by the anterior pituitary gland and, as noted above, influences the growth, regeneration and repair of cells, bones, muscles and organs throughout the body throughout life. Production peaks at adolescence when accelerated growth is occurring and if growing children are deficient in human growth hormone, they remain as pituitary dwarfs. If they have too much they exhibit gigantism (acromegaly).
As is the case with many of our other hormones or their pre-cursors, such as testosterone, oestrogen, progesterone, DHEA and melatonin, hGH levels decline with age.
Therapeutically, many of these hormones can be replaced to offset some of the effects of aging such as menopausal symptoms in women or erectile dysfunction in men.
3 Date Recue/Date Received 2020-06-05 The human body, like every other living entity, works on a daily, or circadian as well as monthly and annual rhythms. Daily growth hormone secretion diminishes with age with roughly half the levels at age forty that we had when we were twenty, and about one-third of those youthful levels at age sixty. In some sixty-year olds the levels are as low as 25% of the hGH levels in a twenty-year old. Symptoms of aging include loss of muscle, increase of fat, decreased physical mobility, decreased energy levels and as a result, diminished socialization, diminished healing ability and an increased risk of cardiovascular disease and decreased life expectancy.
Low hGH levels are associated with the aging process and early onset of disease. For example, Rosen and Bengtsson noted an increased death rate from cardiovascular disease in hGH
deficient patients (Rosen, T., Bengtsson, B. A., Lancet 336 (1990): 285-2880).
Furthermore, the mechanism of hGH release has been elucidated and is considered to be under the control of Growth Hormone Releasing Hormone (GHRH) and Somatostatin. Somatostatin prevents further release of hGH from the pituitary gland. It has been postulated that one of the key factors in aging is an imbalance in the levels of GHRH and Somatostatin in the combined GHRH/Somatostatin secretion, with an increased action or effectiveness of Somatostatin over GHRH. This leads to an effective reduction in release of the stored hGH from the anterior pituitary gland. lsidori et al have shown the selected amino acids arginine and lysine increase the release of the body's own stored, natural hGH, when taken orally. Matteini showed even low doses of arginine in the region of 200 mg can elevate hGH release.
(Matteini, M., et al.
Bollettino-Societa ltaliana Biologia Sperimentale. 56(21):2254-60, Nov. 15, 1980). It has been suggested one of the mechanisms of action is the inhibitory effect of arginine, and possibly other amino acids, on the secretion and action of Somastostatin (Alba-Roth, J., Muller, 0. A., Schopohl, J. et al. Journal of Clinical Endocrinology and Metabolism 67, #6 (1998): 1186-1189).
hGH, once released by the pituitary gland, travels in the circulation and is taken up principally by the liver where it stimulates the production of IGF-1. IGF-1 is then released into the circulation where it attaches to cells in the body and like insulin, triggers the cell to produce certain responses which, with IGF-1, are those of growth, regeneration and repair. Levels of IGF-1 are monitored by the hypothalamus situated just above the pituitary gland. When
Low hGH levels are associated with the aging process and early onset of disease. For example, Rosen and Bengtsson noted an increased death rate from cardiovascular disease in hGH
deficient patients (Rosen, T., Bengtsson, B. A., Lancet 336 (1990): 285-2880).
Furthermore, the mechanism of hGH release has been elucidated and is considered to be under the control of Growth Hormone Releasing Hormone (GHRH) and Somatostatin. Somatostatin prevents further release of hGH from the pituitary gland. It has been postulated that one of the key factors in aging is an imbalance in the levels of GHRH and Somatostatin in the combined GHRH/Somatostatin secretion, with an increased action or effectiveness of Somatostatin over GHRH. This leads to an effective reduction in release of the stored hGH from the anterior pituitary gland. lsidori et al have shown the selected amino acids arginine and lysine increase the release of the body's own stored, natural hGH, when taken orally. Matteini showed even low doses of arginine in the region of 200 mg can elevate hGH release.
(Matteini, M., et al.
Bollettino-Societa ltaliana Biologia Sperimentale. 56(21):2254-60, Nov. 15, 1980). It has been suggested one of the mechanisms of action is the inhibitory effect of arginine, and possibly other amino acids, on the secretion and action of Somastostatin (Alba-Roth, J., Muller, 0. A., Schopohl, J. et al. Journal of Clinical Endocrinology and Metabolism 67, #6 (1998): 1186-1189).
hGH, once released by the pituitary gland, travels in the circulation and is taken up principally by the liver where it stimulates the production of IGF-1. IGF-1 is then released into the circulation where it attaches to cells in the body and like insulin, triggers the cell to produce certain responses which, with IGF-1, are those of growth, regeneration and repair. Levels of IGF-1 are monitored by the hypothalamus situated just above the pituitary gland. When
4 Date Recue/Date Received 2020-06-05 maximal hGH levels are attained for any individual, these levels trigger the release of Somatostatin. This feedback loop prevents excessive levels of hGH in the body.
This feedback loop is extremely efficient at monitoring and maintaining the hGH (and therefore IGF-1) at the optimal level for the individual.
In the prior art, United States patent no. 6,346,264 to Philip White discloses a nutritional supplement comprising an amino acid stack secretagogue which, taken orally, stimulated the pituitary gland to produce hGH/Somatropin, so as to elevate hGH/Somatropin release. The amino acid gamma-aminobutyric acid ("GABA") is also known in the prior art, recently having been approved for use in human nutritional supplements.
It is thus one object of the present disclosure to provide an improved nutritional supplement for elevating hGH release, in particular an amino acid stack including GABA, for a synergistic, well tolerated supplemental having the result of increasing or elevating hGH
release in those individuals where hGH release rates have slowed as a function of increasing age.
Summary The present disclosure relates to an improved nutritional supplement. It is an amino acid stack secretagogue, including the addition of GABA, which, taken orally, stimulates the pituitary gland to produce hGH/Somatotropin. One object of the present disclosure is to elevate hGH/Somatotropin release. This has the further result of increasing IGF-1 levels. Further objects of the present disclosure may also result, namely, inhibiting insulin depression; inhibiting hyperglycaemia and increasing insulin effectiveness; enhancing fat conversion, assisting in lowering cholesterol, and normalizing lipid balance. Particular benefits observed from taking the nutritional supplement including the addition of GABA may include, but are not limited to, improved sleep quality, increased weight loss, increased energy throughout the day, improved nail growth and structure, and/or improved mood.
In summary, the improved nutritional supplement for restoring growth hormone levels of the present disclosure comprises in combination, or, alternatively, consists essentially of in
This feedback loop is extremely efficient at monitoring and maintaining the hGH (and therefore IGF-1) at the optimal level for the individual.
In the prior art, United States patent no. 6,346,264 to Philip White discloses a nutritional supplement comprising an amino acid stack secretagogue which, taken orally, stimulated the pituitary gland to produce hGH/Somatropin, so as to elevate hGH/Somatropin release. The amino acid gamma-aminobutyric acid ("GABA") is also known in the prior art, recently having been approved for use in human nutritional supplements.
It is thus one object of the present disclosure to provide an improved nutritional supplement for elevating hGH release, in particular an amino acid stack including GABA, for a synergistic, well tolerated supplemental having the result of increasing or elevating hGH
release in those individuals where hGH release rates have slowed as a function of increasing age.
Summary The present disclosure relates to an improved nutritional supplement. It is an amino acid stack secretagogue, including the addition of GABA, which, taken orally, stimulates the pituitary gland to produce hGH/Somatotropin. One object of the present disclosure is to elevate hGH/Somatotropin release. This has the further result of increasing IGF-1 levels. Further objects of the present disclosure may also result, namely, inhibiting insulin depression; inhibiting hyperglycaemia and increasing insulin effectiveness; enhancing fat conversion, assisting in lowering cholesterol, and normalizing lipid balance. Particular benefits observed from taking the nutritional supplement including the addition of GABA may include, but are not limited to, improved sleep quality, increased weight loss, increased energy throughout the day, improved nail growth and structure, and/or improved mood.
In summary, the improved nutritional supplement for restoring growth hormone levels of the present disclosure comprises in combination, or, alternatively, consists essentially of in
5 Date Recue/Date Received 2020-06-05 combination the following free amino acids (alternatively in the "L" form such as L-Glutamine):
lysine, ornithine, glutamine, glycine, leucine, iso-leucine, valine and gamma-aminobutyric acid;
and may also include arginine.
In one aspect, the present disclosure is a nutritional supplement for ingestion by humans for restoring growth hormone levels including or alternatively consisting essentially of:
(a) branched chain amino acids chosen from the group leucine, isoleucine, and valine;
(b) free form amino acids chosen from the group lysine, glutamine, ornithine, arginine, and glycine; and (c) gamma-aminobutyric acid.
In a further aspect of the present disclosure, the nutritional supplement for ingestion by humans for restoring growth hormone levels includes or alternatively may consist essentially of all of the amino acids leucine, isoleucine, valine, lysine, glutamine, ornithine, glycine and gamma-aminobutyric acid; and may also include arginine.
In a daily dosage the nutritional supplement may include or alternatively consist essentially of:
(a) 1302 mg of L-Lysine HCI;
(b) 1302 mg of L-Arginine HCI;
(c) 798 mg of L-Ornithine HCI;
(d) 500 mg of Glycine;
(e) 250 mg of L-Glutamine;
(f) 400 mg of L-Leucine;
(g) 400 mg of L-Isoleucine;
(h) 400 mg of L-Valine; and (i) 100 mg of GABA.
In alternative formulations, a daily dosage of the nutritional supplement will include, or consist essentially of:
lysine, ornithine, glutamine, glycine, leucine, iso-leucine, valine and gamma-aminobutyric acid;
and may also include arginine.
In one aspect, the present disclosure is a nutritional supplement for ingestion by humans for restoring growth hormone levels including or alternatively consisting essentially of:
(a) branched chain amino acids chosen from the group leucine, isoleucine, and valine;
(b) free form amino acids chosen from the group lysine, glutamine, ornithine, arginine, and glycine; and (c) gamma-aminobutyric acid.
In a further aspect of the present disclosure, the nutritional supplement for ingestion by humans for restoring growth hormone levels includes or alternatively may consist essentially of all of the amino acids leucine, isoleucine, valine, lysine, glutamine, ornithine, glycine and gamma-aminobutyric acid; and may also include arginine.
In a daily dosage the nutritional supplement may include or alternatively consist essentially of:
(a) 1302 mg of L-Lysine HCI;
(b) 1302 mg of L-Arginine HCI;
(c) 798 mg of L-Ornithine HCI;
(d) 500 mg of Glycine;
(e) 250 mg of L-Glutamine;
(f) 400 mg of L-Leucine;
(g) 400 mg of L-Isoleucine;
(h) 400 mg of L-Valine; and (i) 100 mg of GABA.
In alternative formulations, a daily dosage of the nutritional supplement will include, or consist essentially of:
6 Date Recue/Date Received 2020-06-05 (a) Lysine in the mass range 500 mg and 1500 mg;
(b) Arginine in the mass range 500 mg and 1500 mg;
(c) Ornithine in the mass range 500 mg and 1500 mg;
(d) Glutamine in the mass range 200 mg and 1000 mg;
(e) Glycine in the mass range 400 mg and 1000 mg;
(f) Leucine in the mass range 400 mg and 1000 mg;
(g) lso-leucine in the mass range 400 mg and 1000 mg;
(h) Valine in the mass range 400 mg and 1000 mg; and (i) GABA in the mass range 100 mg and 200 mg.
Detailed Description As noted above, elevating hGH levels elevates IGF-1 levels. This can be achieved by secretagogue hGH releasers without the need for injection therapy or oral-hGH
forms, or gene manipulation. Secretagogues maintain the body's own natural feedback loop, thus not only releasing hGH naturally but safely. Natural secretagogues may have the ability to more closely mimic the body's youthful hGH secretion patterns than any other hGH therapies currently available. Use of a secretagogue such as the supplement of the present disclosure has the potential for restoring the body's hGH and IGF-1 levels without interfering with the body's own feedback loop. The supplement of the present disclosure contains amino acids, formulated as a dietary supplement.
Some amino acids can be made in the body from basic building blocks, but others (nine out of the twenty needed for protein building) are called essential amino acids as the body is unable to manufacture them and they have to be supplied in the food that we eat.
Arginine is an amino acid important in creating synthesis. Claims for Arginine include an increase in fat-burning and muscle-building, as well as strengthening the thymus gland by increasing its weight and activity and thereby boosting immunity. There are also claims that Arginine alone will promote healing of burns and wounds as well as enhance male fertility.
(b) Arginine in the mass range 500 mg and 1500 mg;
(c) Ornithine in the mass range 500 mg and 1500 mg;
(d) Glutamine in the mass range 200 mg and 1000 mg;
(e) Glycine in the mass range 400 mg and 1000 mg;
(f) Leucine in the mass range 400 mg and 1000 mg;
(g) lso-leucine in the mass range 400 mg and 1000 mg;
(h) Valine in the mass range 400 mg and 1000 mg; and (i) GABA in the mass range 100 mg and 200 mg.
Detailed Description As noted above, elevating hGH levels elevates IGF-1 levels. This can be achieved by secretagogue hGH releasers without the need for injection therapy or oral-hGH
forms, or gene manipulation. Secretagogues maintain the body's own natural feedback loop, thus not only releasing hGH naturally but safely. Natural secretagogues may have the ability to more closely mimic the body's youthful hGH secretion patterns than any other hGH therapies currently available. Use of a secretagogue such as the supplement of the present disclosure has the potential for restoring the body's hGH and IGF-1 levels without interfering with the body's own feedback loop. The supplement of the present disclosure contains amino acids, formulated as a dietary supplement.
Some amino acids can be made in the body from basic building blocks, but others (nine out of the twenty needed for protein building) are called essential amino acids as the body is unable to manufacture them and they have to be supplied in the food that we eat.
Arginine is an amino acid important in creating synthesis. Claims for Arginine include an increase in fat-burning and muscle-building, as well as strengthening the thymus gland by increasing its weight and activity and thereby boosting immunity. There are also claims that Arginine alone will promote healing of burns and wounds as well as enhance male fertility.
7 Date Recue/Date Received 2020-06-05 Arginine along with Lysine have been demonstrated to cause hGH release when combined in specific proportions. Essential amino acids contained in the supplement of the present disclosure are lsoleucine, Leucine, Lysine and Valine. Lysine boosts the effectiveness of Arginine and is also said to affect growth as well as having immune-boosting properties of its own.
.. Ornithine can be synthesized in the body and is now also known to help stimulate hGH release.
Glutamine can also be synthesized in the body but may not always be made by the body in sufficient quantities in times of stress. Without sufficiently available levels, the gastrointestinal tract does not function as well, and nutrients are less well absorbed. GABA, which in recent years has been approved for use in human nutritional supplements, is also known to act as an effective hGH releaser and confers a relaxing, calming effect, somewhat similar to the effects of the amino acid tryptophan. Both GABA and tryptophan are neurotransmitter precursors, and may be effective in treating anxiety and stress. Other amino acids in the supplement of the present disclosure contribute to the effects of the supplement and the synergy of the amino acids listed above. This type of combination of amino acids is known as an amino acid stack.
The supplement of the present disclosure works as a dietary supplement by assisting the body's own ability to secrete hGH naturally in a manner which is safe and effective as well as being affordable. When starting the supplement of the present disclosure it should be taken for a minimum of three months, preferably along with a dietary and exercise regime in order to ensure maximal benefits. Continued usage is suggested for maximum benefit and it is also recommended that it be taken on a six month cycle followed by one month off, or six days per week with one day off, based on our current state of knowledge. The supplement of the present disclosure may be formulated in a capsule form for ease of ingestion.
It should be taken on an empty stomach, either before bed or first thing in the morning, for best results. This ensures that it is rapidly absorbed into the bloodstream.
What is not taught nor suggested in the prior art, and which the supplement of the present disclosure provides is the use, in the below disclosed combination and proportions, of amino acids including GABA, lysine, glutamine and ornithine, alternatively to also include arginine, to inhibit insulin depression, often seen when hGH levels are elevated. The supplement of the
.. Ornithine can be synthesized in the body and is now also known to help stimulate hGH release.
Glutamine can also be synthesized in the body but may not always be made by the body in sufficient quantities in times of stress. Without sufficiently available levels, the gastrointestinal tract does not function as well, and nutrients are less well absorbed. GABA, which in recent years has been approved for use in human nutritional supplements, is also known to act as an effective hGH releaser and confers a relaxing, calming effect, somewhat similar to the effects of the amino acid tryptophan. Both GABA and tryptophan are neurotransmitter precursors, and may be effective in treating anxiety and stress. Other amino acids in the supplement of the present disclosure contribute to the effects of the supplement and the synergy of the amino acids listed above. This type of combination of amino acids is known as an amino acid stack.
The supplement of the present disclosure works as a dietary supplement by assisting the body's own ability to secrete hGH naturally in a manner which is safe and effective as well as being affordable. When starting the supplement of the present disclosure it should be taken for a minimum of three months, preferably along with a dietary and exercise regime in order to ensure maximal benefits. Continued usage is suggested for maximum benefit and it is also recommended that it be taken on a six month cycle followed by one month off, or six days per week with one day off, based on our current state of knowledge. The supplement of the present disclosure may be formulated in a capsule form for ease of ingestion.
It should be taken on an empty stomach, either before bed or first thing in the morning, for best results. This ensures that it is rapidly absorbed into the bloodstream.
What is not taught nor suggested in the prior art, and which the supplement of the present disclosure provides is the use, in the below disclosed combination and proportions, of amino acids including GABA, lysine, glutamine and ornithine, alternatively to also include arginine, to inhibit insulin depression, often seen when hGH levels are elevated. The supplement of the
8 Date Recue/Date Received 2020-06-05 present disclosure in the specified combination and having the specified quantity of glutamine inhibits hyperglycaemia, while ensuring a natural anabolic muscle building effect by increasing insulin effectiveness. In the supplement of the present disclosure ornithine is combined with glutamine to enhance fat conversion and assist in lowering cholesterol, while normalizing lipid balance. In the supplement of the present disclosure, in the specified combination and quantities, amino acids are stacked amino acid secretagogues resulting in balancing glucose, insulin and blood lipids. The supplement of the present disclosure includes the branched-chain amino acids leucine, isoleucine and valine so as to provide essential nutrients for muscle regeneration and repair. This is of particular importance when a secretagogue is used before exercise.
The combination of types of amino acids, mass ranges and specific formulations have been selected to be synergistically balanced and of adequate quantity to achieve the desired physiological effect, namely, growth hormone release. Improper combinations of the amino acids or insufficient quantities of amino acid salts will be ineffective. The component amino acids are synergistic in the sense that several of them when combined together, GABA, arginine, lysine, glutamine, ornithine and glycine, synergistically stimulate the release of human growth hormone. The combination was also chosen to inhibit chemical combination or reaction between the amino acids. Such will not occur because of the crystalline free-form amino acid salts that have been chosen.
A further novel aspect of the supplement of the present disclosure is the addition of the sulphur-containing branch-chain amino acids leucine, iso-leucine and valine, all of which themselves have a synergistic effect in combination with the human growth hormone that is released in helping to build and improve muscles mass and strength.
With regard to the individual amino acids in particular, ornithine is synergistic with arginine in elevating hGH levels as is lysine synergistic with arginine in elevating hGH
levels. Glutamine will elevate hGH levels independently and there is some evidence of a synergistic effect with the three others mentioned above with glycine also producing independent induction of hGH
The combination of types of amino acids, mass ranges and specific formulations have been selected to be synergistically balanced and of adequate quantity to achieve the desired physiological effect, namely, growth hormone release. Improper combinations of the amino acids or insufficient quantities of amino acid salts will be ineffective. The component amino acids are synergistic in the sense that several of them when combined together, GABA, arginine, lysine, glutamine, ornithine and glycine, synergistically stimulate the release of human growth hormone. The combination was also chosen to inhibit chemical combination or reaction between the amino acids. Such will not occur because of the crystalline free-form amino acid salts that have been chosen.
A further novel aspect of the supplement of the present disclosure is the addition of the sulphur-containing branch-chain amino acids leucine, iso-leucine and valine, all of which themselves have a synergistic effect in combination with the human growth hormone that is released in helping to build and improve muscles mass and strength.
With regard to the individual amino acids in particular, ornithine is synergistic with arginine in elevating hGH levels as is lysine synergistic with arginine in elevating hGH
levels. Glutamine will elevate hGH levels independently and there is some evidence of a synergistic effect with the three others mentioned above with glycine also producing independent induction of hGH
9 Date Recue/Date Received 2020-06-05 secretion and synergy with the others. The three sulphur-containing branch-chain amino acids, leucine, iso-leucine and valine all have been shown to promote muscle tissue repair and growth particularly in conjunction with human growth hormone as well as increased muscle energy and improvement in skin and wound healing. This in turn would of course help with exercise as vigorous exercise induces a mild level of muscle damage resulting in the aching effect that people notice when they have not been exercising for a while and start to exercise.
GABA is an inhibitory neruotransmitter in the brain. Too much excitation in the brain can lead to restlessness, irritability and insomnia. Advantageously, GABA is able to induce relaxation, analgesia and improve sleep cycles, leading to more restful sleep, which in turn assists with boosting the body's ability to elevate hGH levels because increasing the length and quality of sleep leads to increased hGH production.
Altogether the product is unique in its combination of amino acids in a free-form crystalline state, avoiding an interaction or chain reaction between the amino acids which could result in deterioration and breakdown in the integrity of the product. As well this form avoids the possibility of interaction with the vegetarian gel cap in which the product may be packaged.
In one preferred embodiment, the supplement of the present disclosure formulation for a one day dose, in 6-8 size 00 capsules, includes the following amino acids in the specified approximate mass ranges:
LYSINE 500mg ¨ 1500mg ORNITHI NE 500mg ¨ 1500 mg GLUTAMINE 200mg ¨ 1000mg GLYCINE 400mg ¨ 1500mg LEUCINE 400mg ¨ 1000mg ISO-LEUCINE 400mg ¨ 1000mg VALI NE 400mg ¨ 1000mg GABA 100mg ¨ 200mg Date Recue/Date Received 2020-06-05 Another preferred embodiment may further include:
ARGININE 500 mg-1500 mg In particular, in one preferred embodiment, the nutritional supplement of the present disclosure may have the following specific mass composition:
1302 mg of L-Lysine HCI;
1302 mg of L-Arginine HCI;
798 mg of L-Ornithine HCI;
500 mg of Glycine;
250 mg of L-Glutamine;
400 mg of L-Leucine;
400 mg of L-Isoleucine;
400 mg of L-Valine; and 100 mg of GABA.
As will be apparent to those skilled in the art in the light of the foregoing disclosure, many alterations and modifications are possible in the practice of this disclosure without departing from the spirit or scope thereof. Accordingly, the scope of the disclosure is to be construed in accordance with the substance defined by the following claims.
Date Recue/Date Received 2020-06-05
GABA is an inhibitory neruotransmitter in the brain. Too much excitation in the brain can lead to restlessness, irritability and insomnia. Advantageously, GABA is able to induce relaxation, analgesia and improve sleep cycles, leading to more restful sleep, which in turn assists with boosting the body's ability to elevate hGH levels because increasing the length and quality of sleep leads to increased hGH production.
Altogether the product is unique in its combination of amino acids in a free-form crystalline state, avoiding an interaction or chain reaction between the amino acids which could result in deterioration and breakdown in the integrity of the product. As well this form avoids the possibility of interaction with the vegetarian gel cap in which the product may be packaged.
In one preferred embodiment, the supplement of the present disclosure formulation for a one day dose, in 6-8 size 00 capsules, includes the following amino acids in the specified approximate mass ranges:
LYSINE 500mg ¨ 1500mg ORNITHI NE 500mg ¨ 1500 mg GLUTAMINE 200mg ¨ 1000mg GLYCINE 400mg ¨ 1500mg LEUCINE 400mg ¨ 1000mg ISO-LEUCINE 400mg ¨ 1000mg VALI NE 400mg ¨ 1000mg GABA 100mg ¨ 200mg Date Recue/Date Received 2020-06-05 Another preferred embodiment may further include:
ARGININE 500 mg-1500 mg In particular, in one preferred embodiment, the nutritional supplement of the present disclosure may have the following specific mass composition:
1302 mg of L-Lysine HCI;
1302 mg of L-Arginine HCI;
798 mg of L-Ornithine HCI;
500 mg of Glycine;
250 mg of L-Glutamine;
400 mg of L-Leucine;
400 mg of L-Isoleucine;
400 mg of L-Valine; and 100 mg of GABA.
As will be apparent to those skilled in the art in the light of the foregoing disclosure, many alterations and modifications are possible in the practice of this disclosure without departing from the spirit or scope thereof. Accordingly, the scope of the disclosure is to be construed in accordance with the substance defined by the following claims.
Date Recue/Date Received 2020-06-05
Claims (5)
1. A nutritional supplement for ingestion by humans for restoring growth hormone levels consisting of unmodified rapidly absorbed free-form amino acids, in an amino acid stack which does not include non-amino acid nutritional supplementation, and which, when digested by a user, stimulates release of human growth hormone in the user, said amino acids consisting of:
(a) branched chain amino acids chosen from the group:
(i). leucine, (ii). isoleucine, (iii). valine; and (b) free form amino acids chosen from the group:
(i). lysine, (ii). glutamine, (iii). ornithine, (iv). arginine, (v). glycine; and (c) the free form amino acid gamma-aminobutyric acid.
(a) branched chain amino acids chosen from the group:
(i). leucine, (ii). isoleucine, (iii). valine; and (b) free form amino acids chosen from the group:
(i). lysine, (ii). glutamine, (iii). ornithine, (iv). arginine, (v). glycine; and (c) the free form amino acid gamma-aminobutyric acid.
2. A nutritional supplement for ingestion by humans for restoring growth hormone levels consisting of unmodified rapidly absorbed free-form crystalline amino acids, in an amino acid stack which does not include non-amino acid nutritional supplementation, and which, when digested by a user, stimulates release of human growth hormone in the user, wherein said amino acids consist of the amino acids leucine, isoleucine, valine, lysine, glutamine, ornithine, glycine and gamma-aminobutyric acid.
Date Recue/Date Received 2020-06-05
Date Recue/Date Received 2020-06-05
3. A nutritional supplement for ingestion by humans for restoring growth hormone levels consisting of unmodified rapidly absorbed free-form amino acids, in an amino acid stack which does not include non-amino acid nutritional supplementation, and which, when digested by a user, stimulates release of human growth hormone in the user, said amino acids consisting of the amino acids leucine, isoleucine, valine, lysine, glutamine, ornithine, glycine, arginine and gamma-aminobutyric acid.
4. A nutritional supplement for restoring growth hormone levels, the supplement to be ingested orally by humans in a daily dosage and consisting of unmodified rapidly absorbed free-form crystalline amino acids, in an amino acid stack which does not include non-amino acid nutritional supplementation, and which, when digested by a user, stimulates release of human growth hormone in the user, wherein said amino acids in the daily dosage consist of:
(a) 1302 mg of L-Lysine HCI;
(b) 1302 mg of L-Arginine HCI;
(c) 798 mg of L-Ornithine HCI;
(d) 500 mg of Glycine;
(e) 250 mg of L-Glutamine;
(f) 400 mg of L-Leucine;
(g) 400 mg of L-Isoleucine;
(h) 400 mg of L-Valine; and (i) 100 mg of Gamma-aminobutyric acid
(a) 1302 mg of L-Lysine HCI;
(b) 1302 mg of L-Arginine HCI;
(c) 798 mg of L-Ornithine HCI;
(d) 500 mg of Glycine;
(e) 250 mg of L-Glutamine;
(f) 400 mg of L-Leucine;
(g) 400 mg of L-Isoleucine;
(h) 400 mg of L-Valine; and (i) 100 mg of Gamma-aminobutyric acid
5. A nutritional supplement for restoring growth hormone levels, the supplement to be ingested orally by humans in a daily dosage consisting of unmodified rapidly absorbed free-form amino acids, in an amino acid stack which does not include non-amino acid nutritional supplementation, and which, when digested by a user, stimulates release of Date Recue/Date Received 2020-06-05 human growth hormone in the user, wherein said amino acids in the daily dosage consist of:
(a) Lysine in the mass range 500 mg and 1500 mg;
(b) Arginine in the mass range 500 mg and 1500 mg;
(c) Ornithine in the mass range 500 mg and 1500 mg;
(d) Glutamine in the mass range 200 mg and 1000 mg;
(e) Glycine in the mass range 400 mg and 1000 mg;
(f) Leucine in the mass range 400 mg and 1000 mg;
(g) lso-leucine in the mass range 400 mg and 1000 mg;
(h) Valine in the mass range 400 mg and 1000 mg; and (i) Gamma-aminobutyric acid in the mass range 100 mg and 200 mg.
Date Recue/Date Received 2020-06-05
(a) Lysine in the mass range 500 mg and 1500 mg;
(b) Arginine in the mass range 500 mg and 1500 mg;
(c) Ornithine in the mass range 500 mg and 1500 mg;
(d) Glutamine in the mass range 200 mg and 1000 mg;
(e) Glycine in the mass range 400 mg and 1000 mg;
(f) Leucine in the mass range 400 mg and 1000 mg;
(g) lso-leucine in the mass range 400 mg and 1000 mg;
(h) Valine in the mass range 400 mg and 1000 mg; and (i) Gamma-aminobutyric acid in the mass range 100 mg and 200 mg.
Date Recue/Date Received 2020-06-05
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3081988A CA3081988A1 (en) | 2020-06-05 | 2020-06-05 | Supplement including gamma-aminobutyric acid for restoring growth hormone levels |
US17/339,468 US20210379001A1 (en) | 2020-06-05 | 2021-06-04 | Supplement including gamma-aminobutyric acid for restoring growth hormone levels |
CA3121082A CA3121082A1 (en) | 2020-06-05 | 2021-06-04 | Supplement including gamma-aminobutyric acid for restoring growth hormone levels |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3081988A CA3081988A1 (en) | 2020-06-05 | 2020-06-05 | Supplement including gamma-aminobutyric acid for restoring growth hormone levels |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3081988A1 true CA3081988A1 (en) | 2021-12-05 |
Family
ID=78822766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3081988A Abandoned CA3081988A1 (en) | 2020-06-05 | 2020-06-05 | Supplement including gamma-aminobutyric acid for restoring growth hormone levels |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA3081988A1 (en) |
-
2020
- 2020-06-05 CA CA3081988A patent/CA3081988A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6346264B1 (en) | Supplement for restoring growth hormone levels | |
US20220072096A1 (en) | Whey protein micelles against muscle atrophy and sarcopenia | |
US8734864B2 (en) | Methods for increasing human growth hormone levels | |
US10292964B2 (en) | Compositions for increasing human growth hormone levels | |
TW201417808A (en) | Methods for increasing endurance and fat metabolism in humans | |
TW201417804A (en) | Methods and compositions for increasing sex steroids and growth hormones | |
TW201424728A (en) | Compositions and methods for increasing human growth hormone levels | |
WO2004112511A2 (en) | Supplement for restoring growth hormone levels | |
CA3121082A1 (en) | Supplement including gamma-aminobutyric acid for restoring growth hormone levels | |
CA3081988A1 (en) | Supplement including gamma-aminobutyric acid for restoring growth hormone levels | |
US20150045432A1 (en) | Dietary supplement comprising amino acids in a palatable liquid formulation that promotes restful sleep, recovery from stress and exercise and strengthens the immune system | |
NL2025679B1 (en) | Electrical stimulation for preventing or treating nitric oxide deficiency related conditions | |
CN111035017A (en) | Oral liquid for preventing and treating muscle loss | |
WO2014068296A1 (en) | Fat loss composition | |
JPH05509323A (en) | Composition for the treatment of catabolic conditions comprising authentic IGF-1 and a caloric nutrient | |
CA3216989A1 (en) | Nutritional compositions for preserving muscle mass | |
RU2021111065A (en) | COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF, AT LEAST ONE N-ACETYLCYSTEINE OR DERIVATIVE THEREOF, AND AT LEAST ONE NICOTINAMIDRIBOZIDE OR NAD+ PRECURSOR | |
Factor | Insulin-Like Growth Factor | |
Stokel | New research substantiates the anti-aging properties of DHEA | |
Johnson | Nutrition, Muscle Mass, and Muscular Performance in Middle Age and Beyond |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20231206 |